AbCellera Biologics

AbCellera Biologics

Biotechnology
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

$4.2B

Market Cap • 10/2/2026

2012

(14 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Canada

Canada

Country

Valuation

P/B

4,7

P/S

63,7

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,9

EPS

—

Market Cap

Market Cap

4,2B

EV

3,8B

EV/Revenue

57,5

EV/EBITDA

-19,7

EV/EBIT

-16,9

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-128,1M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

298,9%

Capex/Revenue

37,4%

Capex/D&A

75,9%

Capex/OCF

-26,1%

SBC/OCF

—

% PPE

31,9%

% Goodwill

3,7%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-31,8%

Leverage

N.D./EBITDA

2,1

Debt/Equity

0%

Current Ratio

12,8

Quick Ratio

10,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium